ATE232869T1 - Tricyclische delta3-piperidine als alpha2- antagonisten - Google Patents

Tricyclische delta3-piperidine als alpha2- antagonisten

Info

Publication number
ATE232869T1
ATE232869T1 AT99950627T AT99950627T ATE232869T1 AT E232869 T1 ATE232869 T1 AT E232869T1 AT 99950627 T AT99950627 T AT 99950627T AT 99950627 T AT99950627 T AT 99950627T AT E232869 T1 ATE232869 T1 AT E232869T1
Authority
AT
Austria
Prior art keywords
piperidines
alpha2 antagonists
delta3
tricyclic
tricyclic delta3
Prior art date
Application number
AT99950627T
Other languages
English (en)
Inventor
Ludo Edmond J Kennis
Den Keybus F M A Van
Josephus C Mertens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE232869T1 publication Critical patent/ATE232869T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AT99950627T 1998-10-06 1999-10-01 Tricyclische delta3-piperidine als alpha2- antagonisten ATE232869T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203370 1998-10-06
PCT/EP1999/007419 WO2000020421A2 (en) 1998-10-06 1999-10-01 TRICYCLIC Δ3-PIPERIDINES AS α2-ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE232869T1 true ATE232869T1 (de) 2003-03-15

Family

ID=8234191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950627T ATE232869T1 (de) 1998-10-06 1999-10-01 Tricyclische delta3-piperidine als alpha2- antagonisten

Country Status (30)

Country Link
US (1) US6495555B1 (de)
EP (1) EP1119571B1 (de)
JP (1) JP4590101B2 (de)
KR (1) KR20010071843A (de)
CN (1) CN1131230C (de)
AR (1) AR024216A1 (de)
AT (1) ATE232869T1 (de)
AU (1) AU760502B2 (de)
BG (1) BG64872B1 (de)
BR (1) BR9913507A (de)
CA (1) CA2345622C (de)
CZ (1) CZ20011104A3 (de)
DE (1) DE69905478T2 (de)
DK (1) DK1119571T3 (de)
EE (1) EE04770B1 (de)
ES (1) ES2193751T3 (de)
HU (1) HUP0104002A3 (de)
ID (1) ID28032A (de)
IL (1) IL142443A0 (de)
NO (1) NO20011270D0 (de)
NZ (1) NZ510115A (de)
PL (1) PL347894A1 (de)
PT (1) PT1119571E (de)
RU (1) RU2230744C2 (de)
SI (1) SI1119571T1 (de)
SK (1) SK285585B6 (de)
TR (1) TR200100952T2 (de)
TW (1) TWI248441B (de)
UA (1) UA69420C2 (de)
WO (1) WO2000020421A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269337T1 (de) * 1998-10-06 2004-07-15 Janssen Pharmaceutica Nv Trizyclische delta3-pyridine als arzneimittel
US20050203100A1 (en) * 2002-04-03 2005-09-15 Jukka Sallinen Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
JP4816453B2 (ja) 2004-04-12 2011-11-16 大正製薬株式会社 環状アミン化合物
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. 3−アミノベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(vr1)활성 저해제
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
MX2011012190A (es) 2009-05-14 2011-12-08 Janssen Pharmaceutica Nv Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa.
CA2934134A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
JP2017501164A (ja) * 2013-12-19 2017-01-12 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピペリジニルテトラヒドロキノリン類
SG11201604978QA (en) 2013-12-19 2016-07-28 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
CN114276359B (zh) * 2022-01-05 2023-05-05 浙江大学 一种1,2,3,4-四氢苯并[4,5]呋喃[2,3-c]吡啶衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU926914A1 (ru) * 1980-05-26 1992-04-23 Научно-исследовательский институт фармакологии АМН СССР Производные 1,2,3,4-тетрагидробензофуро[3,2-с]-пиридина или хлоргидрат, обладающие р дом свойств анальгетиков и антагонистов морфина
DE3522959A1 (de) * 1985-06-27 1987-01-08 Merck Patent Gmbh Indolderivate
US4673680A (en) * 1985-09-18 1987-06-16 Pendleton Robert G α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility
EP0339959A3 (de) * 1988-04-27 1991-03-20 Glaxo Group Limited Laktam-Derivate
US4971974A (en) * 1988-06-16 1990-11-20 Neurex Corporation Benzothiophenes as appetite suppressants
US5100891A (en) * 1991-01-18 1992-03-31 Hoechst-Roussel Pharmaceuticals Inc. Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[B]indoles and related compounds
WO1998024791A1 (en) * 1996-12-06 1998-06-11 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds
WO1999033804A1 (en) * 1997-12-25 1999-07-08 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole derivatives
ATE269337T1 (de) * 1998-10-06 2004-07-15 Janssen Pharmaceutica Nv Trizyclische delta3-pyridine als arzneimittel

Also Published As

Publication number Publication date
ES2193751T3 (es) 2003-11-01
EE200100209A (et) 2002-06-17
SK285585B6 (sk) 2007-04-05
NO20011270L (no) 2001-03-13
DK1119571T3 (da) 2003-05-26
CA2345622A1 (en) 2000-04-13
AU6334199A (en) 2000-04-26
RU2230744C2 (ru) 2004-06-20
HUP0104002A3 (en) 2003-12-29
CZ20011104A3 (cs) 2001-12-12
JP2002526545A (ja) 2002-08-20
NZ510115A (en) 2002-11-26
PL347894A1 (en) 2002-04-22
EP1119571B1 (de) 2003-02-19
SI1119571T1 (en) 2003-08-31
AR024216A1 (es) 2002-09-25
IL142443A0 (en) 2002-03-10
JP4590101B2 (ja) 2010-12-01
HK1038010A1 (en) 2002-03-01
WO2000020421A3 (en) 2000-08-03
SK4322001A3 (en) 2002-01-07
PT1119571E (pt) 2003-06-30
TR200100952T2 (tr) 2001-10-22
TWI248441B (en) 2006-02-01
CA2345622C (en) 2007-12-04
KR20010071843A (ko) 2001-07-31
ID28032A (id) 2001-05-03
US6495555B1 (en) 2002-12-17
WO2000020421A2 (en) 2000-04-13
NO20011270D0 (no) 2001-03-13
BG105332A (en) 2001-11-30
DE69905478D1 (de) 2003-03-27
DE69905478T2 (de) 2004-03-18
EP1119571A2 (de) 2001-08-01
CN1131230C (zh) 2003-12-17
EE04770B1 (et) 2007-02-15
CN1332744A (zh) 2002-01-23
UA69420C2 (uk) 2004-09-15
BR9913507A (pt) 2001-06-05
BG64872B1 (bg) 2006-07-31
AU760502B2 (en) 2003-05-15
HUP0104002A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
EE200200082A (et) Uued spiroühendid
NO20003706D0 (no) Ny tricyklisk forbindelse
EP0986385A4 (de) Antagonisten des gonadorelins
DE69719354D1 (de) Muscarin-antagonisten
ID30132A (id) Turunan-turunan pirazol trisiklik
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
DE69911259D1 (de) Tricyclische benzodiazepine als vasopressin antagonisten
NO991821D0 (no) Substituerte tricykliske forbindelser
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
DK0804440T3 (da) Tricykliske benzazapin-vasopressionantagonister
EE200000171A (et) Uued NPY antagonistid
DK0839806T3 (da) Substituerede tricykliske forbindelser
ATE221052T1 (de) Tetrahydrochinolinderivate als eaa antagonisten
DE59813430D1 (de) Perylenhydrazidimide als Carbonylderivatisierungsreagenzien
DE69718786D1 (de) Benzoxazinone als dopamine -d4- rezeptor-antagonisten
DE69626220D1 (de) 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten
PT1144411E (pt) Compostos espiro anti-histaminicos
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
NO991823D0 (no) Substituerte tricykliske forbindelser
DE59808461D1 (de) Oxazolidinone als 5-ht2a-antagonisten
NO20022847D0 (no) Nye substituerte tricykliske forbindelser
DE69735811D1 (de) Piperazinoderivate als neurokinin-antagonisten
DE69905478D1 (de) Tricyclische delta3-piperidine als alpha2-antagonisten
DE60009931D1 (de) Muscarin-antagonisten
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1119571

Country of ref document: EP

REN Ceased due to non-payment of the annual fee